Investors / United States / Frazier Life Sciences
Frazier Life Sciences
Venture capital · Palo Alto, CA, United States · North America
Frazier Life Sciences is a healthcare investment firm that manages venture capital and public equity strategies. Its venture strategy builds and invests in early-stage private biopharmaceutical companies, while its public equity strategy is a long-only, evergreen strategy focused on publicly traded biopharmaceutical companies and private crossover opportunities.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticshealthcareoncologyradiopharmaceuticalspublic equities
Your fit with Frazier Life Sciences
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsFrazier Life Sciences lists 78 checked portfolio companies on its own site and is named in 17 funding rounds, 6 of them as lead. Its most frequent entry is Growth, 44% of the companies with a known first round. Its largest themes are Healthcare & Biotech (99%) and Food & Agriculture (1%). 84% of its companies are based in United States. It invests most often alongside RA Capital, Longitude Capital and Foresite Capital.
Counts come from funding rounds that name Frazier Life Sciences, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Frazier Life Sciences' whole history. Rounds on record name 16 companies; its own site lists 78. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 31% |
| Series B | 25% |
| Growth | 44% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 1 | 1 |
| '25 | 7 | 0 |
| '26 | 9 | 5 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 93th | 78 companies |
| Recent activity | 95th | 11 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 90th | 18% of companies confirmed by a round |
| Sector focus | 97th | 99% in its largest sector |
| Reach | 88th | 7 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 17 |
| Longitude Capital | 9 |
| Foresite Capital | 8 |
| Aisling Capital | 6 |
| NEA | 6 |
| ARCH Venture Partners | 5 |
| Altamont Pharmaceutical Holdings | 5 |
| Avoro Capital Advisors | 5 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers6381%
- No longer answers00%
- Points to another company1519%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 99% | 15% |
| Food & Agriculture | 1% | 3% |
Co-investor network
who it backs companies with, and who they back togetherCompare Frazier Life Sciences head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Frazier Life Sciences| Date | Company | Stage |
|---|---|---|
| 22 Jul 2026 | Series B Led | |
| 24 Jun 2026 | Series A Led | |
| 20 May 2026 | Series A | |
| 24 Mar 2026 | Series A Led | |
| 13 Mar 2026 | Series A | |
| 5 Feb 2026 | Series C+ Led | |
| 8 Jan 2026 | Series B | |
| 8 Jan 2026 | Series C+ |
Round details for Frazier Life Sciences
Amounts, full round histories and every co-investor in Frazier Life Sciences' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
78 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| The company designs and develops ligand traps that target Activin x GDF biology to treat diseases such as pulmonary hypertension, heart failure and obesity. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Portfolio page | ||||
| AirNexis is developing AN01, a dry powder inhaler for COPD | Healthcare & Biotech | Portfolio page | ||
| Akero Therapeutics is pioneering novel therapies to transform the lives of people living with serious metabolic diseases | Healthcare & Biotech | Portfolio page | ||
| Alcresta Therapeutics develops rare disease, enzyme-based products helping to address fat malabsorption in patients who are enterally fed at home or in the hospital. | Healthcare & Biotech | Portfolio page | ||
| Alentis Therapeutics is a clinical-stage biotech company that treats cancer and reverses fibrosis by developing anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies | Healthcare & Biotech | Portfolio page | ||
| Alesta Therapeutics is a biotech company developing novel oral small molecule therapies for underserved rare diseases. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Amicus Therapeutics is a subsidiary of BioMarin Pharmaceutical Inc. focused on delivering medicines for people living with genetically defined conditions | Healthcare & Biotech | Portfolio page | ||
| AnaptysBio manages financial collaborations with pharmaceutical companies | Healthcare & Biotech | Portfolio page | ||
| Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | Healthcare & Biotech | Feb 2026Series C+ | Page + round | |
Food & Agriculture | Portfolio page | |||
| Architect Therapeutics pursues life-changing oral therapies by targeting disease drivers that have been difficult-to-drug with existing chemistry | Healthcare & Biotech | Portfolio page | ||
| Arcutis Biotherapeutics develops targeted therapies for chronic immune-driven skin diseases. | Healthcare & Biotech | Portfolio page | ||
| Aspen Neuroscience develops personalized cell therapies for Parkinson's disease using stem cell biology and genomics | Healthcare & Biotech | Nov 2025Series C+ | Page + round | |
| Attovia Therapeutics is developing next-generation biotherapeutics for immune-mediated diseases. | Healthcare & Biotech | Apr 2025Series C+ | Page + round | |
| Avidity Biosciences is developing RNA therapeutics for rare muscle diseases | Healthcare & Biotech | Portfolio page | ||
| The company is developing a treatment for hypertrophic cardiomyopathy | Healthcare & Biotech | Nov 2025Series A | Page + round | |
| BridgeBio develops medicines for genetic conditions | Healthcare & Biotech | Portfolio page |
About this data
site last read 10 Nov 2026- Site
- frazierls.com
- Last read
- 10 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 3 Dec 2024
- Companies checked
- 78
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Frazier Life Sciences' profile as data
Pull Frazier Life Sciences' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/frazierls.com
# also
GET /v1/firms/frazierls.com/portfolio
GET /v1/firms/frazierls.com/coinvestors
GET /v1/firms/frazierls.com/news